Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

Dermatology

Volumn 231, Issue 2, 2015, Pages 184-190

  Zouboulis, Christos C ^a   Del Marmol, Veronique ^a,c   Mrowietz, Ulrich ^a,b   Prens, Errol P ^a,d   Tzellos, Thrasivoulos ^a,e   Jemec, Gregor B E ^a,f  

^a DESSAU MEDICAL CENTER   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c ERASME HOSPITAL   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Acne inversa; Classification; Clinical signs; Diagnostic criteria; Hidradenitis suppurativa; Severity assessment

Indexed keywords

ANTIINFLAMMATORY AGENT;

ACNE INVERSA; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CLINICAL PRACTICE; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSESSMENT; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ERYSIPELAS; HUMAN; LABORATORY TEST; LYMPHEDEMA; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PYODERMA; QUALITY OF LIFE; SEPSIS; SKIN DISEASE; SOFT TISSUE INFECTION; SUPPURATIVE HIDRADENITIS; CLASSIFICATION; HIDRADENITIS SUPPURATIVA; SEVERITY OF ILLNESS INDEX;

ANTI-INFLAMMATORY AGENTS; HIDRADENITIS SUPPURATIVA; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 84939571040     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000431175     Document Type: Article

References (32)

1. Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366. 158-164
2. Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinology 2010; 2. 9-16
3. Kurzen H, Kurokawa I, Jemec GBE, Emtestam L, Sellheyer K, Giamarellos-Bourboulis EJ, Nagy I, Bechara FG, Sartorius K, Lapins J, Krahl D, Altmeyer P, Revuz J, Zouboulis CC. What causes hidradenitis suppurativa? Exp Dermatol 2008; 17. 455-472
4. Naldi L. Epidemiology; in Jemec G, Revuz J, Leyden J (eds). Hidradenitis Suppurativa. Berlin, Springer, 2006, vol 1, pp 58-64
5. Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, Poli F, Faye O, Roujeau JC, Bonnelye G, Grob JJ, Bastuji-Garin S. Prevalence and factors associated with hidradenitis suppurativa. results from two case-control studies. J Am Acad Dermatol 2008; 59. 596-601
6. Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35. 191-194
7. Vinding GR, Miller IM, Zarchi K, Ibler KS, Ellervik C, Jemec GB. The prevalence of inverse recurrent suppuration. a populationbased study of possible hidradenitis suppurativa. Br J Dermatol 2014; 170. 884-889
8. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23. 985-998
9. Yu C, Cook M. Hidradenitis suppurativa. a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122. 763-769
10. Schrader AM, Deckers IE, van der Zee HH, Boer J, Prens EP. Hidradenitis suppurativa. a retrospective study of 846 Dutch patients to identify factors associated with disease severity. J Am Acad Dermatol 2014; 71. 460-467
11. Cosmatos I, Matcho A, Weinstein R , Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol 2013; 68. 412-419
12. Vazquez BG, Alikhan A, Weaver AL , Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors. a populationbased study of Olmsted County, Minnesota. J Invest Dermatol 2013; 133. 97-103
13. Palmer RA, Keefe M. Early-onset hidradenitis suppurativa. Clin Exp Dermatol 2001; 26. 501-503
14. Deckers IE, van der Zee HH, Boer J, Prens EP. Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement. J Am Acad Dermatol 2015; 72. 485-488
15. Zouboulis CC, Tsatsou F. Disorders of the apocrine sweat glands; in Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (eds). Fitzpatrick's Dermatology in General Medicine, ed 8.. New York, McGraw-Hill, 2012, pp 947-959
16. Zouboulis CC, Bechara FG, Fritz K, Kurzen H, Liakou AI, Marsch WC, Milling A, Nast A, Podda M, Taube KM, Wienert V, Winkler T. S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa (ICD-10 Ziffer. L73.2). J Dtsch Dermatol Ges 2012; 10(suppl 5):S1-S31
17. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhasz I, Lapins J, Matusiak L, Prens EP, Revuz J, Schneider-Burrus S, Szepietowski JC, van der Zee HH, Jemec GBE. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015; 29. 619-644
18. Zouboulis CC, Adams DA, Gu Y, Goldblum OM. High-sensitivity c-reactive protein response to adalimumab in hidradenitis suppurativa patients. J Invest Dermatol 2012; 132:S88
19. Wortsman X, Jemec GB. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007; 33. 1340-1342
20. Wortsman X, Jemec G. A 3D ultrasound study of sinus tract formation in hidradenitis suppurativa. Dermatol Online J 2013; 19. 18564
21. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus. surgical approach; in Roenigk RK, Roenigk HH Jr (eds). Dermatologic Surgery. Principles and Practice, ed 2. New York, Dekker, 1996, pp 623-645
22. Kimball AB, Kerdel F, Adams D , Mrowietz U, Gelfand JM, Gniadecki R, Prens EP, Schlessinger J, Zouboulis CC, van der Zee HH, Rosenfeld M, Mulani P, Gu Y, Paulson S, Okun M, Jemec GBE. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa. a parallel randomized trial. Ann Intern Med 2012; 157. 846-855
23. Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol 2014; 171. 1434-1442
24. Williams ST, Busby RC, De Muth RJ, Nelson H. Perineal hidradenitis suppurativa. presentation of two unusual complications and a review. Ann Plast Surg 1991; 26. 456-462
25. Constantinou C, Widom K, Desantis J, Obmann M. Hidradenitis suppurativa complicated by squamous cell carcinoma. Am Surg 2008; 74. 1177-1181
26. Deckers IE, van der Zee HH, Prens EP. Severe fatigue based on anaemia in patients with hidradenitis suppurativa. report of two cases and a review of the literature. J Eur Acad Dermatol Venereol, Epub ahead of print
27. Esmann S, Jemec GBE. Psychosocial impact of hidradenitis suppurativa. a qualitative study. Acta Derm Venereol 2011; 91. 328-332
28. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa. a comprehensive review. J Am Acad Dermatol 2009; 60. 539-563
29. Kurek A, Johanne Peters EM, Sabat R, Sterry W, Schneider-Burrus S. Depression is a frequent co-morbidity in patients with acne inversa. J Dtsch Dermatol Ges 2013; 11. 743-750
30. Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa. a Canadian study. Am J Clin Dermatol 2015; 16. 61-65
31. Shlyankevich J, Chen AJ, Kim GE, Kimball AB. Hidradenitis suppurativa is a systemic disease with substantial comorbidity burden. a chart-verified case-control analysis. J Am Acad Dermatol 2014; 71. 1144-1150
32. Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, Jemec GBE. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol 2014; 150. 1273-1280